S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
Log in
OTCMKTS:MLCPF

Medipharm Labs Stock Forecast, Price & News

$0.66
+0.08 (+13.79 %)
(As of 01/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.60
Now: $0.66▼
$0.69
50-Day Range
$0.38
MA: $0.64▼
$2.57
52-Week Range
$2.57
Now: $0.66▼
$2.57
Volume2.64 million shs
Average Volume181,345 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
MediPharm Labs Corp. primarily focuses on producing pharma-grade cannabis oil and concentrates in Canada. It also focuses on providing cannabis contract processing services to licensed producers and growers; supplying cannabis oil to companies for sale under its brand; and supplying raw materials and processing for the creation of ready-to-sell cannabis products. The company was founded in 2015 and is headquartered in Barrie, Canada.

MarketRank™

Overall MarketRank™

0.22 out of 5 stars

Health Services Sector

4th out of 4 stocks

Pharmaceuticals: Other Industry

6th out of 6 stocks

Analyst Opinion: 0.0Community Rank: 1.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceuticals: Other
Sub-IndustryN/A
SectorHealth Services
Current SymbolOTCMKTS:MLCPF
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.medipharmlabs.com
Phone705-719-7425
Employees28

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable
$0.66
+0.08 (+13.79 %)
(As of 01/14/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MLCPF News and Ratings via Email

Sign-up to receive the latest news and ratings for MLCPF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Medipharm Labs (OTCMKTS:MLCPF) Frequently Asked Questions

What stocks does MarketBeat like better than Medipharm Labs?

Wall Street analysts have given Medipharm Labs a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Medipharm Labs wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Medipharm Labs' key competitors?

Some companies that are related to Medipharm Labs include Daiichi Sankyo (DSNKY), ePlus (PLUS), Ono Pharmaceutical (OPHLY), OTCMKTS:WDEXF (WDEXF) and Otsuka (OTSKF).
View all of MLCPF's competitors.

Who are Medipharm Labs' key executives?

Medipharm Labs' management team includes the following people:
  • Mr. Patrick McCutcheon, Founder, CEO & Chairman
  • Mr. Keith Strachan, Co-Founder, Pres & Director
  • Mr. Christopher J. Hobbs C.A., CA, CFO & Director (Age 53)
  • Mr. David J. Mayers, Chief Operating Officer
  • Mr. Kirk Binns, Exec. VP of Global Accounts

What is Medipharm Labs' stock symbol?

Medipharm Labs trades on the OTCMKTS under the ticker symbol "MLCPF."

How do I buy shares of Medipharm Labs?

Shares of MLCPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Medipharm Labs' stock price today?

One share of MLCPF stock can currently be purchased for approximately $0.66.

What is Medipharm Labs' official website?

The official website for Medipharm Labs is www.medipharmlabs.com.

How can I contact Medipharm Labs?

The company can be reached via phone at 705-719-7425.

This page was last updated on 1/15/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.